MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD JNCE
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Again Named to Dow Jones Sustainability World Index
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
Tickers ACLX GILD
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story